Ultra-High-Throughput Screening Explained | Technology Networks
Ultra-High-Throughput Screening Explained | Technology Networks
https://www.technologynetworks.com/tn/articles/crispr-based-screening-in-drug-discovery-411429
Publish Date: 2026-04-08 13:53:00
Source Domain: www.technologynetworks.com
CRISPR-based screening in drug discovery provides a robust methodology for unbiased, high-throughput interrogation of gene function. This technology enables researchers to identify and validate therapeutic targets effectively. By utilizing programmable endonucleases and guide RNA libraries, laboratory professionals can systematically disrupt, inhibit, or activate genes across diverse biological models. This approach improves preclinical efficiency by generating functional genomic data early in development.
How does CRISPR screening improve pipeline efficiency?
This screening approach accelerates pipeline progression by linking specific genetic perturbations directly to observable phenotypic changes in cellular models. This direct linkage enables researchers to identify novel drug targets, elucidate mechanisms of action, and uncover the genetic determinants of drug resistance. The methodology has largely superseded traditional RNA interference (RNAi) in many applications due to its superior specificity, lower off-target rates, and robust ablation of protein expression in knockout models.
To execute a typical workflow, researchers deliver a complex library of single guide RNAs (sgRNAs) into a cell population expressing a Cas nuclease. This critical step ensures precise protospacer adjacent motif (PAM) recognition. Next, scientists subject the cells to selective pressure, such as a cytotoxic drug treatment, environmental stress, or targeted viral infection. They then quantify the relative enrichment or depletion of specific sgRNAs to identify the exact genes that mediate the targeted biological response.
This systematic interrogation helps laboratory personnel eliminate false-positive targets early in the preclinical drug development process. Reducing clinical attrition rates requires high-confidence target validation, which these functional genomic screens provide across various disease models. Regulatory organizations, including the Food and…
